MA54458B1 - Formes cristallines et formes salines d'un inhibiteur de kinase - Google Patents
Formes cristallines et formes salines d'un inhibiteur de kinaseInfo
- Publication number
- MA54458B1 MA54458B1 MA54458A MA54458A MA54458B1 MA 54458 B1 MA54458 B1 MA 54458B1 MA 54458 A MA54458 A MA 54458A MA 54458 A MA54458 A MA 54458A MA 54458 B1 MA54458 B1 MA 54458B1
- Authority
- MA
- Morocco
- Prior art keywords
- crystalline
- relates
- compound
- kinase inhibitor
- salt forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des formes cristallines de la base libre de l'inhibiteur de c-Met, Composé 1. L'invention concerne également des formes cristallines de sels du Composé 1. L'invention concerne également des compositions pharmaceutiques comprenant les polymorphes solides de la base libre et des sels du Composé 1. L'invention concerne en outre des méthodes de traitement d'une maladie, d'un trouble ou d'un syndrome médié au moins en partie par la modulation de l'activité in vivo d'une protéine kinase.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862779430P | 2018-12-13 | 2018-12-13 | |
| US201962856469P | 2019-06-03 | 2019-06-03 | |
| EP19836338.4A EP3894012B1 (fr) | 2018-12-13 | 2019-12-12 | Formes cristallines et formes salines d'un inhibiteur de kinase |
| PCT/US2019/065972 WO2020123800A1 (fr) | 2018-12-13 | 2019-12-12 | Formes cristallines et formes salines d'un inhibiteur de kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA54458A MA54458A (fr) | 2021-10-20 |
| MA54458B1 true MA54458B1 (fr) | 2025-09-30 |
Family
ID=69160358
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA54458A MA54458B1 (fr) | 2018-12-13 | 2019-12-12 | Formes cristallines et formes salines d'un inhibiteur de kinase |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US12017995B2 (fr) |
| EP (2) | EP4631505A3 (fr) |
| JP (2) | JP7509779B2 (fr) |
| KR (2) | KR20250103803A (fr) |
| CN (1) | CN113329790A (fr) |
| AU (2) | AU2019395419B2 (fr) |
| BR (1) | BR112021011333A2 (fr) |
| CA (1) | CA3122840A1 (fr) |
| CL (1) | CL2021001537A1 (fr) |
| CO (1) | CO2021007613A2 (fr) |
| CR (1) | CR20210375A (fr) |
| DK (1) | DK3894012T3 (fr) |
| ES (1) | ES3052838T3 (fr) |
| FI (1) | FI3894012T3 (fr) |
| GE (1) | GEP20247596B (fr) |
| HR (1) | HRP20251122T1 (fr) |
| HU (1) | HUE072868T2 (fr) |
| IL (2) | IL320433A (fr) |
| LT (1) | LT3894012T (fr) |
| MA (1) | MA54458B1 (fr) |
| MD (1) | MD3894012T2 (fr) |
| MX (1) | MX2021006951A (fr) |
| PE (1) | PE20211757A1 (fr) |
| PH (1) | PH12021551356A1 (fr) |
| PL (1) | PL3894012T3 (fr) |
| PT (1) | PT3894012T (fr) |
| RS (1) | RS67216B1 (fr) |
| SG (1) | SG11202105949RA (fr) |
| SI (1) | SI3894012T1 (fr) |
| SM (1) | SMT202500346T1 (fr) |
| TW (1) | TWI852963B (fr) |
| WO (1) | WO2020123800A1 (fr) |
| ZA (1) | ZA202103844B (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4647127A3 (fr) * | 2018-01-26 | 2025-12-17 | Exelixis, Inc. | Composés pour le traitement de troubles dépendant de la kinase |
| BR112021024300A2 (pt) * | 2019-06-03 | 2022-01-11 | Exelixis Inc | Formas de sais cristalinas de um inibidor de quinase |
| BR112022021712A2 (pt) * | 2020-04-30 | 2022-12-06 | Exelixis Inc | Processos para a preparação de um inibidor de quinase |
| BR112023001792A2 (pt) | 2020-07-31 | 2023-04-11 | Exelixis Inc | Combinações para o tratamento de câncer |
| KR20230104186A (ko) * | 2020-11-05 | 2023-07-07 | 엑셀리시스, 인코포레이티드 | 키나제 억제제의 약제학적 조성물 |
| CN112650176B (zh) * | 2020-12-22 | 2022-08-30 | 天能化工有限公司 | 一种盐酸解析开停车工序的dcs控制方法 |
| TW202334090A (zh) * | 2021-11-03 | 2023-09-01 | 美商艾克塞里克斯公司 | 用於治療激酶依賴性病症之化合物 |
| CA3240202A1 (fr) | 2021-12-22 | 2023-06-29 | Kirsten Phizackerley | Formes cristallines et formes salines d'un inhibiteur de kinase |
| CN116751161A (zh) * | 2023-06-28 | 2023-09-15 | 中国人民解放军军事科学院军事医学研究院 | 喹啉类化合物及其制备方法、药物组合物及医药用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2925655T3 (es) * | 2003-09-26 | 2022-10-19 | Exelixis Inc | Moduladores c-Met y métodos de uso |
| CA2604238C (fr) | 2005-04-15 | 2015-07-07 | Neogenix Oncology, Inc. | Anticorps monoclonaux recombines et antigenes correspondants contre les cancers du colon et du pancreas |
| BRPI0920261A8 (pt) | 2008-10-14 | 2016-01-19 | Xi Ning | Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica |
| KR20250123237A (ko) | 2009-01-16 | 2025-08-14 | 엑셀리시스, 인코포레이티드 | 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
| CN102408411B (zh) | 2011-09-19 | 2014-10-22 | 北京康辰药业股份有限公司 | 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用 |
| CN114507282B (zh) | 2012-10-04 | 2025-05-16 | 达纳－法伯癌症研究所公司 | 人单克隆抗-pd-l1抗体和使用方法 |
| HUE053069T2 (hu) | 2013-05-02 | 2021-06-28 | Anaptysbio Inc | Programozott halál-1 (PD-1) ellen irányuló ellenanyagok |
| US10501418B2 (en) | 2014-02-14 | 2019-12-10 | Exelixis, Inc. | Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use |
| CN104817497B (zh) | 2015-03-20 | 2017-03-08 | 南京众睿缘生物科技有限公司 | 一种炔代喹啉衍生物及其制备方法和用途 |
| JP7166292B2 (ja) | 2017-05-26 | 2022-11-07 | エグゼリクシス， インコーポレイテッド | Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法 |
| EP4647127A3 (fr) * | 2018-01-26 | 2025-12-17 | Exelixis, Inc. | Composés pour le traitement de troubles dépendant de la kinase |
| BR112021024300A2 (pt) * | 2019-06-03 | 2022-01-11 | Exelixis Inc | Formas de sais cristalinas de um inibidor de quinase |
-
2019
- 2019-12-12 WO PCT/US2019/065972 patent/WO2020123800A1/fr not_active Ceased
- 2019-12-12 GE GEAP201915695A patent/GEP20247596B/en unknown
- 2019-12-12 AU AU2019395419A patent/AU2019395419B2/en active Active
- 2019-12-12 HR HRP20251122TT patent/HRP20251122T1/hr unknown
- 2019-12-12 MD MDE20211022T patent/MD3894012T2/ro unknown
- 2019-12-12 PE PE2021000862A patent/PE20211757A1/es unknown
- 2019-12-12 PL PL19836338.4T patent/PL3894012T3/pl unknown
- 2019-12-12 BR BR112021011333-9A patent/BR112021011333A2/pt unknown
- 2019-12-12 ES ES19836338T patent/ES3052838T3/es active Active
- 2019-12-12 IL IL320433A patent/IL320433A/en unknown
- 2019-12-12 SM SM20250346T patent/SMT202500346T1/it unknown
- 2019-12-12 CA CA3122840A patent/CA3122840A1/fr active Pending
- 2019-12-12 FI FIEP19836338.4T patent/FI3894012T3/fi active
- 2019-12-12 LT LTEPPCT/US2019/065972T patent/LT3894012T/lt unknown
- 2019-12-12 SI SI201930963T patent/SI3894012T1/sl unknown
- 2019-12-12 KR KR1020257021669A patent/KR20250103803A/ko active Pending
- 2019-12-12 HU HUE19836338A patent/HUE072868T2/hu unknown
- 2019-12-12 CN CN201980090041.5A patent/CN113329790A/zh active Pending
- 2019-12-12 RS RS20250909A patent/RS67216B1/sr unknown
- 2019-12-12 MX MX2021006951A patent/MX2021006951A/es unknown
- 2019-12-12 IL IL283860A patent/IL283860B2/en unknown
- 2019-12-12 PT PT198363384T patent/PT3894012T/pt unknown
- 2019-12-12 EP EP25183289.5A patent/EP4631505A3/fr active Pending
- 2019-12-12 EP EP19836338.4A patent/EP3894012B1/fr active Active
- 2019-12-12 MA MA54458A patent/MA54458B1/fr unknown
- 2019-12-12 CR CR20210375A patent/CR20210375A/es unknown
- 2019-12-12 US US17/312,658 patent/US12017995B2/en active Active
- 2019-12-12 SG SG11202105949RA patent/SG11202105949RA/en unknown
- 2019-12-12 DK DK19836338.4T patent/DK3894012T3/da active
- 2019-12-12 JP JP2021533537A patent/JP7509779B2/ja active Active
- 2019-12-12 KR KR1020217021734A patent/KR102828472B1/ko active Active
- 2019-12-13 TW TW108145868A patent/TWI852963B/zh active
-
2021
- 2021-06-04 ZA ZA2021/03844A patent/ZA202103844B/en unknown
- 2021-06-09 PH PH12021551356A patent/PH12021551356A1/en unknown
- 2021-06-10 CO CONC2021/0007613A patent/CO2021007613A2/es unknown
- 2021-06-11 CL CL2021001537A patent/CL2021001537A1/es unknown
-
2023
- 2023-12-27 JP JP2023221085A patent/JP7783870B2/ja active Active
-
2024
- 2024-05-07 US US18/657,052 patent/US20240300897A1/en active Pending
-
2025
- 2025-09-22 AU AU2025234277A patent/AU2025234277A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54458B1 (fr) | Formes cristallines et formes salines d'un inhibiteur de kinase | |
| RU2498988C2 (ru) | Ингибиторы активности протеинтирозинкиназы | |
| MX2023007192A (es) | Inhibidores de prmt5. | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| EA200301232A1 (ru) | Новые соединения арилсульфонамида и их применение для лечения ожирения, диабета типа ii и нарушений центральной нервной системы | |
| MA51627B1 (fr) | Benzofurane, benzopyrrole, benzothiophène substitués et inhibiteurs du complément structurellement apparentés | |
| MA43979B1 (fr) | Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques | |
| NO20061074L (no) | Forbindelser og sammensetninger som inbibitorer av reseptortyrosinkinaseaktivitet | |
| ATE318267T1 (de) | Einige alkylendiamin-substituierte heterocyclen | |
| EA200300528A1 (ru) | 1-арил-или 1-алкилсульфонилгетероциклилбензазолы в качестве лигандов 5-гидрокситриптамина-6 | |
| ZA202108034B (en) | Crystalline salt forms of a kinase inhibitor | |
| BRPI0606690A2 (pt) | composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica | |
| CY1107274T1 (el) | Παραγωγα αλφα-αμινοαμιδιου χρησιμα σαν παραγοντες κατα της ημικρανιας | |
| AR051965A1 (es) | Sales de la n-[2-( { (3r)-1-[trans-4-hidroxi-4-(6- metoxipiridin-3-il)-ciclohexil] pirrolidin-3- il} amino)-2- oxoetil]-3-(trifluormetil) benzamida | |
| DE602006013191D1 (de) | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
| GEAP202516634A (en) | Heteroaryl compounds for the treatment of pain | |
| ATE461697T1 (de) | Phospholipidderivate von valproinsäure und ihre kombinationen | |
| FR3056909B1 (fr) | Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree | |
| EA200301143A1 (ru) | Производные гетероциклилалкокси-, алкилтио- и -алкиламинобензазола в качестве лигандов 5-гидрокситриптамина-6 | |
| EP3620457A4 (fr) | Composé dérivé de pyrimidine, isomère optique, ou sel pharmaceutiquement acceptable de celui-ci, et composition pour prévenir ou traiter une maladie liée au tyro 3 le comprenant en tant que principe actif | |
| CL2023001268A1 (es) | Composiciones farmacéuticas de un inhibidor de cinasa | |
| EA200500045A1 (ru) | Новые соединения, их применение и получение | |
| BR112022015925A2 (pt) | Combinações de compostos beta-lactâmicos, probenecida e ácido valproico e usos dos mesmos | |
| EA202191151A1 (ru) | Новые аминофосфиновые производные в качестве ингибиторов аминопептидазы а | |
| EA202191653A1 (ru) | Кристаллические формы и солевые формы ингибитора киназы |